• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疫苗获取受限对新冠病毒病死亡率的影响——黑山2020年7月至2022年2月新冠病毒病疫苗接种及新冠病毒病所致死亡率的描述性研究

The Impact of Limited Vaccine Access on COVID-19 Mortality-Descriptive Study of COVID-19 Vaccination and Mortality Due to COVID-19 in Montenegro, July 2020-February 2022.

作者信息

Obradović Aleksandar, Raičević Marija, Joksimović Milko

机构信息

Institute for Public Health of Montenegro, 81000 Podgorica, Montenegro.

出版信息

Vaccines (Basel). 2025 Mar 6;13(3):278. doi: 10.3390/vaccines13030278.

DOI:10.3390/vaccines13030278
PMID:40266149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11946242/
Abstract

: The Delta variant of SARS-CoV-2 dominated Montenegro from July 2020 until early 2022, when Omicron took over. COVID-19 vaccination began on 20 February 2021, two months later than in the EU. The study aimed to investigate the impact of vaccination on mortality rates in Montenegro during Delta's predominance. : A descriptive study was conducted using data from the Montenegrin Institute of Public Health COVID-19 database, the Population Electronic Immunization Register, which provides data for all administrated COVID-19 vaccines in Montenegro, and EUROSTAT mortality data. : COVID-19 accounted for 17.8% of total deaths in Montenegro during the period of study. Crude mortality rate among unvaccinated was almost four times higher compared to those who received at least one vaccine dose. Inactivated vaccines were predominantly administered to those aged 60 and over, while RNA vaccines were mainly given to those under 60. The median interval between the last vaccine dose and death was significantly higher for vector vaccines compared to inactivated vaccines. : The delayed start of vaccination and limited vaccine choices in Montenegro likely contributed to prolonged high mortality due to COVID-19. Our findings reveal disparities in vaccine distribution and effectiveness, highlighting the need for timely and equitable access to effective vaccines, especially for vulnerable populations. : The study underscores the importance of prompt vaccine distribution and the option to choose vaccine types in building public trust and reducing mortality rates. It emphasizes the need for strengthening global mechanisms COVAX and continuing educational activities to address vaccine hesitancy and ensure equitable access to effective vaccines.

摘要

2020年7月至2022年初,新冠病毒的德尔塔变异株在黑山占据主导地位,之后被奥密克戎变异株取代。新冠疫苗接种于2021年2月20日开始,比欧盟晚两个月。该研究旨在调查在德尔塔变异株占主导期间,疫苗接种对黑山死亡率的影响。:采用黑山公共卫生研究所新冠病毒数据库、人口电子免疫登记册(提供黑山所有接种的新冠疫苗数据)以及欧盟统计局死亡率数据进行描述性研究。:在研究期间,新冠病毒导致的死亡占黑山总死亡人数的17.8%。未接种疫苗者的粗死亡率几乎是至少接种一剂疫苗者的四倍。灭活疫苗主要接种给60岁及以上人群,而RNA疫苗主要接种给60岁以下人群。与灭活疫苗相比,载体疫苗最后一剂接种至死亡的中位间隔时间明显更长。:黑山疫苗接种开始延迟且疫苗选择有限,可能导致新冠病毒造成的高死亡率持续时间延长。我们的研究结果揭示了疫苗分配和有效性方面的差异,凸显了及时、公平地获取有效疫苗的必要性,尤其是对于弱势群体。:该研究强调了迅速分发疫苗以及选择疫苗类型对于建立公众信任和降低死亡率的重要性。它强调需要加强全球疫苗免疫联盟机制并持续开展教育活动,以解决疫苗犹豫问题并确保公平获取有效疫苗。

相似文献

1
The Impact of Limited Vaccine Access on COVID-19 Mortality-Descriptive Study of COVID-19 Vaccination and Mortality Due to COVID-19 in Montenegro, July 2020-February 2022.疫苗获取受限对新冠病毒病死亡率的影响——黑山2020年7月至2022年2月新冠病毒病疫苗接种及新冠病毒病所致死亡率的描述性研究
Vaccines (Basel). 2025 Mar 6;13(3):278. doi: 10.3390/vaccines13030278.
2
COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.COVID-19 相关住院病例在 SARS-CoV-2 德尔塔和奥密克戎变异株流行期间的种族/民族差异和疫苗接种状况分析——COVID-NET,14 个州,2021 年 7 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):466-473. doi: 10.15585/mmwr.mm7112e2.
3
The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.在英国和美国,针对成年人的 COVID-19 疫苗副作用风险的描述和沟通对疫苗接种意愿的影响:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Sep 6;22(1):592. doi: 10.1186/s13063-021-05484-2.
4
SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causes.SARS-CoV-2 变体和疫苗接种率在 Delta 变体出现期间面临的全球大流行:一项旨在寻找疫苗犹豫原因的全国性调查。
J Infect Public Health. 2022 Jul;15(7):773-780. doi: 10.1016/j.jiph.2022.06.007. Epub 2022 Jun 17.
5
Disparities and effectiveness of COVID-19 vaccine policies in three representative European countries.三个代表性欧洲国家的 COVID-19 疫苗政策的差异和效果。
Int J Equity Health. 2024 Jan 30;23(1):16. doi: 10.1186/s12939-024-02110-w.
6
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.疫苗对 Alpha、Delta 或奥密克戎变异株引起的 SARS-CoV-2 感染或 COVID-19 住院的有效性:一项全国性丹麦队列研究。
PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep.
7
Maternal vaccination against COVID-19 and neonatal outcomes during Omicron: INTERCOVID-2022 study.母亲接种 COVID-19 疫苗与奥密克戎期间新生儿结局的关系:INTERCOVID-2022 研究。
Am J Obstet Gynecol. 2024 Oct;231(4):460.e1-460.e17. doi: 10.1016/j.ajog.2024.02.008. Epub 2024 Feb 16.
8
Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study.mRNA-1273、BNT162b2 和 BBIBP-CorV 疫苗在阿根廷儿童中的有效性,针对 delta 和 omicron 新冠病毒变异株流行期间的感染和死亡:阴性测试、病例对照研究。
BMJ. 2022 Nov 30;379:e073070. doi: 10.1136/bmj-2022-073070.
9
Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.新冠病毒奥密克戎 BA.2 变异株感染、重症和死亡的灭活疫苗和 Ad5-nCoV 新冠疫苗有效性。
BMC Med. 2022 Oct 20;20(1):400. doi: 10.1186/s12916-022-02606-8.
10
COVID-19 Vaccines: How Efficient and Equitable Was the Initial Vaccination Process?新冠疫苗:初始疫苗接种过程的效率和公平性如何?
Vaccines (Basel). 2022 Dec 20;11(1):11. doi: 10.3390/vaccines11010011.

本文引用的文献

1
Determinants of COVID-19 vaccination worldwide: WORLDCOV, a retrospective observational study.全球 COVID-19 疫苗接种的决定因素:回顾性观察研究 WORLDCOV。
Front Public Health. 2023 Aug 31;11:1128612. doi: 10.3389/fpubh.2023.1128612. eCollection 2023.
2
Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.比较三种不同的 COVID-19 疫苗平台(科兴疫苗、BNT162b2 和 Ad5-nCoV)在既往感染 COVID-19 个体与无既往感染 COVID-19 个体中的反应原性和中和抗体。
Immunol Lett. 2022 Dec;251-252:20-28. doi: 10.1016/j.imlet.2022.10.002. Epub 2022 Oct 21.
3
Community Health Resources, Globalization, Trust in Science, and Voting as Predictors of COVID-19 Vaccination Rates: A Global Study with Implications for Vaccine Adherence.
社区卫生资源、全球化、对科学的信任以及投票作为新冠疫苗接种率的预测因素:一项对疫苗接种依从性有影响的全球研究。
Vaccines (Basel). 2022 Aug 18;10(8):1343. doi: 10.3390/vaccines10081343.
4
Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.全球 COVID-19 疫苗不平等:分配第一年的失败及未来的潜在解决方案。
Front Public Health. 2022 Mar 7;10:821117. doi: 10.3389/fpubh.2022.821117. eCollection 2022.
5
Deaths: Leading Causes for 2019.死亡:2019 年的主要死因。
Natl Vital Stat Rep. 2021 Jul;70(9):1-114.
6
Effect of the covid-19 pandemic in 2020 on life expectancy across populations in the USA and other high income countries: simulations of provisional mortality data.2020年新冠疫情对美国及其他高收入国家不同人群预期寿命的影响:临时死亡率数据模拟
BMJ. 2021 Jun 23;373:n1343. doi: 10.1136/bmj.n1343.
7
Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis.针对 SARS-CoV-2 的疫苗在国内的年龄优先排序、全球分配和对公共卫生的影响:一项数学建模分析。
Vaccine. 2021 May 21;39(22):2995-3006. doi: 10.1016/j.vaccine.2021.04.002. Epub 2021 Apr 8.
8
SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.严重急性呼吸综合征冠状病毒2型中和抗体:跨疫苗的网络荟萃分析
Vaccines (Basel). 2021 Mar 5;9(3):227. doi: 10.3390/vaccines9030227.